Global systemwide sales for the fourth quarter were $3.4 billion, a decrease of 8.3%, and for the full year were $14.0 billion, a decrease of 3.5%. International ...
(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results